BioArctic
Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.
BIOA | ST
Overview
Corporate Details
- ISIN(s):
- SE0010323303 (+1 more)
- LEI:
- 549300Y0OI2WVUNHLC33
- Country:
- Sweden
- Address:
- Warfvinges väg 35, 112 51 Stockholm
- Website:
- https://www.bioarctic.se/en/
Description
BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2019-02-04 10:00 |
BioArctic announces that Eisai will initiate Phase 3 confirmatory study with BA…
|
English | 195.9 KB | ||
| 2019-02-04 10:00 |
BioArctic meddelar att Eisai kommer att starta en bekräftande Fas 3-studie med …
|
Swedish | 192.8 KB | ||
| 2018-12-14 08:00 |
BioArctic outlicenses its alpha-synuclein antibody portfolio for Parkinson’s Di…
|
English | 190.5 KB | ||
| 2018-12-14 08:00 |
BioArctic utlicensierar sin portfölj med antikroppar mot alfa-synuklein för Par…
|
Swedish | 204.4 KB | ||
| 2018-11-12 08:00 |
BioArctic is awarded grant from EU’s Horizon 2020 for participation in research…
|
English | 201.5 KB | ||
| 2018-11-12 08:00 |
BioArctic får anslag från EU:s Horizon 2020 för deltagande i forskningskonsorti…
|
Swedish | 201.2 KB | ||
| 2018-11-08 08:00 | Swedish | 520.6 KB | |||
| 2018-11-08 08:00 | English | 535.1 KB | |||
| 2018-11-06 20:00 |
BioArctic presents Nomination Committee and publishes financial calendar 2019
|
English | 187.4 KB | ||
| 2018-11-06 20:00 |
BioArctic presenterar valberedning och offentliggör finansiell kalender 2019
|
Swedish | 180.4 KB | ||
| 2018-11-02 02:30 |
BioArctic’s partner AbbVie exercises its option to license the alpha-synuclein …
|
English | 187.9 KB | ||
| 2018-11-02 02:30 |
BioArctics partner AbbVie utövar sin option att licensiera portföljen med alfa-…
|
Swedish | 202.8 KB | ||
| 2018-10-25 14:30 |
BioArctic announces additional BAN2401 Phase 2b study results in early Alzheime…
|
English | 224.5 KB | ||
| 2018-10-25 14:30 |
BioArctic meddelar ytterligare resultat från Fas 2b-studien med BAN2401 i tidig…
|
Swedish | 222.3 KB | ||
| 2018-10-21 09:00 |
BioArctic får beviljat konceptpatent i Europa för bolagets strategi för sjukdom…
|
Swedish | 178.7 KB |
Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for BioArctic
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for BioArctic via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-02-13 | Gunilla Osswald | Other | Sell | 40,000 | 8,821,200.00 SEK |
| 2025-02-13 | Gunilla Osswald | Other | Other | 40,000 | 3,344,000.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Sell | 6,000 | 1,323,180.00 SEK |
| 2025-02-13 | Sten Mikael Moge | Other | Other | 6,000 | 501,600.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Sell | 1,500 | 330,795.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 2,500 | 209,000.00 SEK |
| 2025-02-13 | Johanna Margareta Fälting | Other | Other | 1,500 | 125,400.00 SEK |
| 2025-01-10 | Mikael Smedeby | Other | Buy | 730 | 148,920.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 2,000 | 446,000.00 SEK |
| 2024-12-19 | Oskar Bosson | Other | Sell | 871 | 195,626.60 SEK |
Peer Companies
